Delivery Order SPE2DB22D9207-SPE2DB25FH5EP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector vials. This firm fixed-price delivery order, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, represents a specific pharmaceutical procurement supporting military healthcare operations. The award carries no...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $13,697.84 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xolair 300 mg/2 ml autoinjector syringes to support the medical supply needs of military healthcare facilities. This Delivery Order is issued under a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $20,546.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xolair 300 mg/2 ml autoinjectors and has an ultimate completion date of January 6, 2025. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which covers a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The delivery order is for Xolair 300 mg/2 ml auto-injectors and is part of a larger $499,999,999 indefinite delivery contract (IDC) under the SPE2DB program that DMS Pharmaceutical Group holds with DLA. This IDC enables DLA to issue delivery orders for a comprehensive range of pharmaceutical products,...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $6,848.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the delivery of Xolair 300 mg/2 ml autoinjector, a specialized biologic medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $27,395.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector medications. This firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of September 10, 2025, and does not utilize a set-aside designation. The award represents a specific fulfillment under DMS Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $34,244.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Xolair 300 mg/2 ml auto-injector products to support the medical needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the...
- The Defense Logistics Agency awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, issued on September 3, 2025, with completion targeted for September 24, 2025, represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The company,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $8,561.15 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The delivery order, which is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, is for the delivery of 4,566,831,826 units of Xolair 300 mg/2 ml autoinjectors. This contract is not associated with any set-aside designation. As a key supplier in...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH5EPDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $34,244.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, was awarded without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 and valid through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products to support military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders from the DLA for branded and generic medications, biologics, and specialty pharmaceutical products including oncology treatments, vaccines, and auto-injectors. The company's positioning as a woman-owned small business has enabled it to compete effectively in federal procurement markets while maintaining a robust portfolio of medical supply deliveries to Department of Defense healthcare facilities across the United States and globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.2k | 9/8/25 |